363 related articles for article (PubMed ID: 17457476)
1. The post-antibiotic effects of linezolid against Gram-positive pathogens.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of staphylococci to linezolid and other antimicrobial agents.
Poiată A; Tuchiluş C; Bădicuţ I; Grigore L; Buiuc D
Roum Arch Microbiol Immunol; 2002; 61(4):293-9. PubMed ID: 15055263
[TBL] [Abstract][Full Text] [Related]
3. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
4. Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid.
Schwameis R; Fille M; Manafi M; Zeitlinger M; Sauermann R
Res Microbiol; 2012 Apr; 163(3):157-60. PubMed ID: 22210435
[TBL] [Abstract][Full Text] [Related]
5. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
Munckhof WJ; Giles C; Turnidge JD
J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
[TBL] [Abstract][Full Text] [Related]
6. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
[TBL] [Abstract][Full Text] [Related]
7. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Allen GP; Bierman BC
Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
[TBL] [Abstract][Full Text] [Related]
8. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
9. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
Dowzicky MJ; Chmelařová E
Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
[TBL] [Abstract][Full Text] [Related]
10. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
13. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
[TBL] [Abstract][Full Text] [Related]
14. Bacteremia caused by an Enterococcus faecalis isolate with high-level linezolid resistance in a teenager with Crohn's disease.
Lopez Marti MG; Jhaveri R
Pediatr Infect Dis J; 2009 Jul; 28(7):663-4. PubMed ID: 19451857
[TBL] [Abstract][Full Text] [Related]
15. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms.
Sandoe JA; Wysome J; West AP; Heritage J; Wilcox MH
J Antimicrob Chemother; 2006 Apr; 57(4):767-70. PubMed ID: 16464896
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
[TBL] [Abstract][Full Text] [Related]
17. Effects of linezolid on staphylococcal adherence versus time of treatment.
Pagano PJ; Buchanan LV; Dailey CF; Haas JV; Van Enk RA; Gibson JK
Int J Antimicrob Agents; 2004 Mar; 23(3):226-34. PubMed ID: 15164962
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of resistance to Melaleuca alternifolia (tea tree) oil and rifampicin in Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis.
Hammer KA; Carson CF; Riley TV
Int J Antimicrob Agents; 2008 Aug; 32(2):170-3. PubMed ID: 18571379
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.
Wiederhold NP; Coyle EA; Raad II; Prince RA; Lewis RE
J Antimicrob Chemother; 2005 May; 55(5):792-5. PubMed ID: 15814598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
